India wants price controls on cancer generics
India's National Pharmaceutical Pricing Authority ( NPPA) requested pricing information on generic cancer drugs from six pharma companies so the agency can fix the products' ceiling prices. The products, which are included on the country's national list of essential medicines, include Refolinon folinic acid from Pfizer Inc. (NYSE:PFE); cyclosporine from Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359) and Cipla Ltd. (Mumbai, India); mercaptopurine from Cipla; and cyclophosphamide, marketed as Endoxan by Drugs Dropship (Haryana, India) and as Cycloxan by Biochem Pharmaceutical Industries Ltd., which is part of Zydus Cadila Group (NSE:CADILAHC; BSE:532321).
The agency requested the information by Thursday. ...